Table 1 Demographic characteristics
From: Outcome of MS relapses in the era of disease-modifying therapy
Sex, n (%) | |
Female | 73 (67.6) |
Male | 35 (32.4) |
Age at relapse onset (years) | 34.7 ± 9.7 |
Clinical course, n (%) | |
CIS | 31 (28.7) |
RRMS | 72 (66.7) |
SPMS | 5 (4.6) |
DMT in RRMS/SPMS, n (%) | |
DMT | 41/77 (53.2) |
No DMT | 36/77 (46.8) |
DMT distribution, n (%) | |
Interferon beta | 15 (36.6) |
Glatiramer acetate | 9 (22.0) |
Fingolimod | 6 (14.6) |
Natalizumab | 4 (9.8) |
B-cell depleting antibodya | 2 (4.9) |
Dimethyl fumarate | 1 (2.4) |
Teriflunomide | 1 (2.4) |
Mitoxantrone | 1 (2.4) |
Interferon + Teriflunomida | 1 (2.4) |
Methylprednisoloneb | 1 (2.4) |
DMT duration (years) | 2.1 ± 2.5 |
Relapses, n | 119 |